Investor Presentation Q1 2018
Investor Presentation
First three months of 2018
Slide 29
Biopharm constitutes 16% of Novo Nordisk sales and a
strategy has been defined to return to growth
DKK
billion
6
5
4
3
2
NovoSevenⓇ and Norditropin®
account for 84% of Biopharm sales¹
Other biopharmaceuticals
| Other haemophilia products
NorditropinⓇ
NovoSevenⓇ
'Return to Growth' strategy builds on organic,
non-organic and organisational initiatives
Return to
growth
in Biopharm
Drive in-market brands beyond
current plans and ensure
successful pipeline launches
Pursue licensing or acquisition of
complementary assets or
companies
Strengthen the organisation to
drive the Biopharm return to
growth agenda
0
Q1
2013
1 Reported sales for the first three months of 2018
changing
diabetes
Q1
2018
novo nordiskView entire presentation